Sun, May 19, 2024
[Archive]
Volume 15, Issue 4 (September 2023 2023)
Iranian Journal of Blood and Cancer 2023, 15(4): 262-271 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ahmadinejad M, Balagholi S, Mashkooli M. The prevalence of Lupus Anticoagulant in Iranian children and adolescents; Current status and literature review of diagnosis. Iranian Journal of Blood and Cancer 2023; 15 (4) :262-271
URL: http://ijbc.ir/article-1-1397-en.html
URL: http://ijbc.ir/article-1-1397-en.html
1- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. , minooam@gmail.com
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
2- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Abstract: (653 Views)
Background: Lupus anticoagulant (LAC) is an acquired IgG or IgM autoimmune antibody against platelet membrane phospholipids. LAC is an important cause of aPTT prolongation in children. We determined the prevalence of LA-positive results in ≤ 18 years patients referred to the Iranian Blood Transfusion Organization (IBTO) special reference coagulation laboratory.
Method: During a period of 27 months all patients ≤ 18 years old who were referred to IBTO and had results of aPTT and LAC were evaluated. LAC test panel included screening tests (aPTT-LA and DRVVT screen) and the mixing test and confirmatory tests (Hexagonal assay and/or DRVVT confirm) all performed by STAGO reagents and instruments. In cases with positive LAC, their follow-up refers to IBTO coagulation lab were evaluated after 12 weeks.
Results: Our data revealed a LAC prevalence of 2.4% in the referred patients ≤ 18 years who had aPTT test result and 31% in those whom the LAC test was performed for them. In more than half of the LA-positive patients, the main reason for referring was an incidental finding of aPTT prolongation noticed before surgery or during hospitalization. Interestingly only 21.6% of the patients with positive LAC results were requested by the physician.
Conclusions: LAC is not infrequent in children and adolescents however in most cases it is a transient problem without any significant clinical findings. Most of the cases (78.4%) were not suspected of LAC by their physicians so it may be frequently missed in children clinically.
: Original Article |
Subject:
Pediatric Surgery
Received: 2023/06/29 | Accepted: 2023/09/18 | Published: 2023/09/27
Received: 2023/06/29 | Accepted: 2023/09/18 | Published: 2023/09/27
References
1. Conley C. A hemorrhagic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621-2.
2. Dhir V, Pinto B. Antiphospholipid syndrome: A review. Journal of Mahatma Gandhi Institute of Medical Sciences. 2014;19(1):19. [DOI:10.4103/0971-9903.126231]
3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;4(2):295-306. [DOI:10.1111/j.1538-7836.2006.01753.x]
4. Dusse LMS, Freitas LG, Rios DRA, Armond SC, Marcolino MS. Antiphospholipid syndrome: a clinical and laboratory challenge. Revista da Associação Médica Brasileira. 2014;60(2):181-6. [DOI:10.1590/1806-9282.60.02.016]
5. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. The Lancet Neurology. 2009;8(11):998-1005. [DOI:10.1016/S1474-4422(09)70239-X]
6. Shi W, Kris S, Chong B, Gordon S, Chesterman C. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Australian and New Zealand journal of medicine. 1990;20(3):231-6. [DOI:10.1111/j.1445-5994.1990.tb01025.x]
7. Male C, Lechner K, Eichinger S, Kyrle PA, Kapiotis S, Wank H, et al. Clinical significance of lupus anticoagulants in children. The Journal of Pediatrics. 1999;134(2):199-205. [DOI:10.1016/S0022-3476(99)70416-6]
8. Cabiedes J, Trejo-Hernández J, Loredo-Abdalá A, Castilla-Serna L, López-Mendoza AT, Cordero-Esperón HA, et al. Anti-Cardiolipin, Anti-Cardiolipin Plus Bovine, or Human β 2 Glycoprotein-I and Anti-Human β 2 Glycoprotein-I Antibodies in a Healthy Infant Population. Archives of medical research. 2002;33(2):175-9. [DOI:10.1016/S0188-4409(01)00359-9]
9. Burk CD, Cohen AR, Miller L, Handler SD. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics. 1992;89(4):691-5. [DOI:10.1542/peds.89.4.691]
10. Ciaudo M, Horellou M, De Carbonnieres C, Conard J, Samama M, Audouin J. Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen: a report of four patients. American journal of hematology. 1991;38(4):271-6. [DOI:10.1002/ajh.2830380404]
11. Ashley S, Kruger A, McMullen KW, Darke S. Prosthetic graft thrombosis associated with lupus anticoagulant. European journal of vascular surgery. 1988;2(1):57-60. [DOI:10.1016/S0950-821X(88)80110-5]
12. Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Current rheumatology reports. 2012;14(1):71-8. [DOI:10.1007/s11926-011-0227-1]
13. Peker E, Kavakli K, Balkan C, Karapinar D, Aydemir B. Incidence and clinical importance of lupus anticoagulant in children with recurrent upper respiratory tract infection. Clinical and Applied Thrombosis/Hemostasis. 2009. [DOI:10.1177/1076029609351292]
14. Mizumoto H, Maihara T, Hiejima E, Shiota M, Hata A, Seto S, et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. European journal of pediatrics. 2006;165(7):484-8. [DOI:10.1007/s00431-006-0117-0]
15. Giordano P, Tesse R, Lassandro G, Fracchiolla D, Ranieri P, Lotito A, et al. Clinical and laboratory characteristics of children positive for antiphospholipid antibodies. Blood Transfusion. 2012;10(3):296.
16. Molta C, Meyer O, Dosquet C, de Oca MM, Babron M-C, Danon F, et al. Childhood-onset systemic lupus erythematosus: antiphospholipid antibodies in 37 patients and their first-degree relatives. Pediatrics. 1993;92(6):849-53. [DOI:10.1542/peds.92.6.849]
17. Shapiro S, Thiagarajan P. Lupus anticoagulants. Progress in hemostasis and thrombosis. 1982;6:263.
18. JUDE B, GOUDEMAND J, DOLLE I, CARON C, WATEL A, TIRY C, et al. Lupus anticoagulant: a clinical and laboratory study of 100 cases. Clinical & Laboratory Haematology. 1988;10(1):41-51. [DOI:10.1111/j.1365-2257.1988.tb01152.x]
19. Kallanagowdar C, Chauhan A, Puertolas MV, Warrier R. Prevalence and Resolution of Lupus Anticoagulant in Children. The Ochsner Journal. 2016;16(2):172-5.
20. Malbora B, Bilaloglu E. Lupus anticoagulant positivity in pediatric patients with prolonged activated partial thromboplastin time: A single-center experience and review of the literature. Pediatric hematology and oncology. 2015;32(7):495-504. [DOI:10.3109/08880018.2015.1065302]
21. Guideline CL. Laboratory testing for the lupus anticoagulant; Approved guideline. CLSI document H60‐A. 2014;2014.
22. Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Annals of the Rheumatic Diseases. 2023 Oct 1;82(10):1258-70. [DOI:10.1136/ard-2023-224609]
23. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832. [DOI:10.1182/blood-2002-02-0441]
24. CURRIMBHOY Z. Transitory anticoagulants in healthy children. Journal of Pediatric Hematology/Oncology. 1984;6(2):210-1. [DOI:10.1097/00043426-198406020-00017]
25. Male C, Lechner K, Eichinger S, Kyrle PA, Kapiotis S, Wank H, Kaider A, Pabinger I. Clinical significance of lupus anticoagulants in children. The Journal of Pediatrics. 1999 Feb 1;134(2):199-205. [DOI:10.1016/S0022-3476(99)70416-6]
26. Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology. 2005 Dec 13;210(10):799-805. [DOI:10.1016/j.imbio.2005.10.012]
27. Venugopalan P, Bushra R, Gravell D. Accidental detection of lupus anticoagulants in children. Ann Trop Paediatr. 2001;21:277-279 [DOI:10.1080/02724930120077880]
28. Ravelli A, Martini A, Burgio GR. Antiphospholipid antibodies in pediatrics. Eur J Pediatr. 1994;153:472-479. [DOI:10.1007/BF01956999]
29. Molta C, Meyer O, Dosquet C, et al. Childhood-onset systemic lupus erythematosus: antiphospholipid antibodies in 37 patients and their first-degree relatives. Pediatrics. 1993;92:849-853. [DOI:10.1542/peds.92.6.849]
30. Seaman DE, Londino AV Jr, Kwoh CK, et al. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics. 1995;96:1040-1045. [DOI:10.1542/peds.96.6.1040]
31. Gattorno M, Buoncompagni A, Molinari AC, et al. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Br J Rheumatol. 1995;34:873-881. [DOI:10.1093/rheumatology/34.9.873]
32. Shergy WJ, Kredich DW, Pisetsky DS. The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. J Rheumatol. 1988;15:1389-1394.
33. Ravelli A, Caporali R, Di Fuccia G, et al. Anticardiolipin antibodies in pediatric systemic lupus erythematosus. Arch Pediatr Adolesc Med. 1994;148:398-402. [DOI:10.1001/archpedi.1994.02170040064011]
34. Dlott JS, Rpubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14:71-78. [DOI:10.1007/s11926-011-0227-1]
35. Brodeur GM, O'Neill PJ,Willimas JA. Acquired inhibitors of coagulation in nonhemophiliac children. J Pediatr. 1980;96:439-441 [DOI:10.1016/S0022-3476(80)80693-7]
36. Orris DJ, Lewis JH, Spero JA, Hasiba U. Blocking coagulation inhibitors in children taking penicillin. J Pediatr. 1980;97:426-429. [DOI:10.1016/S0022-3476(80)80195-8]
37. Pazzola G, Zuily S, Erkan D. The challenge of bleeding in antiphospholipid antibody- positive patients. Curr Rhematol Rep. 2015;17:1-11. [DOI:10.1007/s11926-014-0481-0]
38. Becton DL, Stine KC. Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome. J Pediatr. 1997;130:998-1000 [DOI:10.1016/S0022-3476(97)70291-9]
39. Giordano P, Tesse R, Lassandro G, et al. Clinical and laboratory characteristics of children positive for antiphospholipid antibodies. Blood Transfus. 2012;10:296-301.
40. Burk CD,Miller L, Handler SD, Cohen AR. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics. 1992;89:691-695. [DOI:10.1542/peds.89.4.691]
41. Lee MT, Nardi MA, Hadzi-Nesic J, Karpatkin M. Transient hemorrhagic diathesis associated with and inhibitor of prothrombin with lupus anticoagulant in 1 1/2-year-old girl: report of a case and review of the literature. Am J Hematol. 1996;51:307-314.
https://doi.org/10.1002/(SICI)1096-8652(199604)51:4<307::AID-AJH10>3.0.CO;2-B [DOI:10.1002/(SICI)1096-8652(199604)51:43.0.CO;2-B]
42. Brodeur GM, O'Neill PJ,Willimas JA. Acquired inhibitors of coagulation in nonhemophiliac children. J Pediatr. 1980;96:439-441 [DOI:10.1016/S0022-3476(80)80693-7]
43. Bernini JC, Buchanan GR, Ashcraft J. Hypoprothrombinemia and severe hemorrhage associated with a lupus anticoagulant. J Pediatr. 1993;123:937-939. [DOI:10.1016/S0022-3476(05)80390-7]
44. Bernstein ML, Salusinsky-Sternbach M, Bellefleur M, Esseltine DW. Thrombotic and hemorrhagic complications in children with the lupus anticoagulant. Am J Dis Child. 1984;138:1132-1135 [DOI:10.1001/archpedi.1984.02140500038014]
45. Schmugge M, Tolle S, Marbet GA, et al. Gingival bleeding, epistaxis and haematoma three days after gastroenteritis: the haemorrhagic lupus anticoagulant syndrome. Eur J Pediatr. 2001;160:43-46. [DOI:10.1007/PL00008415]
46. Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica. 1997;82:345-347.
47. Humphries JE, Acker MN, Pinkston JE, Ruddy S. Transient lupus anticoagulant associated with prothrombin deficiency: unusual cause of bleeding in a 5-year-old girl. Am J Pediatr Hematol Oncol. 1994;16:372-376
48. Anderson A, Mohan U, Liesner R. Transient lupus anticoagulant: an unusual cause of bruising in children. Emergency Medicine Journal. 2003;20(5):e6-e. [DOI:10.1136/emj.20.5.e6]
49. Knobe K, Tedgård U, Ek T, Sandström P-E, Hillarp A. Lupus anticoagulants in two children-bleeding due to non phospholipid-dependent antiprothrombin antibodies. European journal of pediatrics. 2012;171(9):1383-7. [DOI:10.1007/s00431-012-1737-1]
50. Bajaj S, Rapaport S, Fierer D, Herbst K, Schwartz D. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983;61(4):684-92.
https://doi.org/10.1182/blood.V61.4.684.bloodjournal614684 [DOI:10.1182/blood.V61.4.684.684]
51. Mingers A, Sutor A. Lupus inhibitors in childhood. Haemostaseologie. 1992;12:101-6. [DOI:10.1055/s-0038-1660324]
52. Manco-Johnson MJ, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr. 1996;128:319-323. [DOI:10.1016/S0022-3476(96)70274-3]
53. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-536. [DOI:10.1016/S0002-9343(96)00060-5]
54. Galli M, Finazzi G, Norbis F, et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost. 1999;81:695-700. [DOI:10.1055/s-0037-1614556]
55. Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back? Cytokine Growth Factor Rev. 2021;60:52-60. [DOI:10.1016/j.cytogfr.2021.05.001]
56. Ansari K, Ghemtiri E, Hamidipour S, Saberianpour S. Thrombocytopenia and coronavirus: A prognosis and progression of the Coronavirus disease. Iranian Journal of Pediatric Hematology and Oncology. 2022 Apr 10;12(2):134-9. [DOI:10.18502/ijpho.v12i2.9078]
57. Gupta D, Chatterjee T, Sharma A, Ganguli P, Das S, Sharma S. Rare case of acquired hemophilia and lupus anticoagulant. Indian J Hematol Blood Transfus. 2014 Sep;30(3):197-200. doi: 10.1007/s12288-012-0204-5. Epub 2012 Oct 9. PMID: 25114408; PMCID: PMC4115089. [DOI:10.1007/s12288-012-0204-5]
58. Chen, V., Roby, L.C., Wentzel, S. et al. Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report. J Med Case Reports 16, 177 (2022). [DOI:10.1186/s13256-022-03402-x]
59. Seidizadeh O, Ahmadinejad M, Homayoun S, Mannucci PM, Peyvandi F. Von Willebrand disease combined with coagulation defects in Iran. Blood Transfus. 2021 Sep;19(5):428-434. doi: 10.2450/2021.0078-21. Epub 2021 May 28. PMID: 34059196; PMCID: PMC8486600
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
